UNIVERSITY OF RHODE ISLAND
Department of Chemistry
SEMINAR

3:00 P.M., Monday, September 18, 2023
Room 105 – Beaupre Center

Dr. Nicholas A. Meanwell

Bristol Myers Squibb

Inhibitors of HIV-1 Maturation: The Invention of Fipravirimat

HOST

Fang Wang
Department of Chemistry
401-874-4243

Dr. Nicholas A. Meanwell

Biography: Dr. Nick Meanwell received his Ph.D. degree in organic chemistry with Dr. Neville Jones from the University of Sheffield, England in 1976 and did his postdoctoral research with Prof. Carl Johnson at Wayne State University. He joined Bristol Myers Squibb (BMS) in 1982, rose through the ranks, and became the Vice President, Discovery Chemistry Platforms at Bristol Myers Squibb Research and Early Development until his retirement in October 2022. During his forty-year tenure at BMS, Nick led many drug discovery programs across several therapeutic areas including cardiovascular, neurosciences, and virology. He and his teams advanced 33 clinical candidates for the prevention of thrombosis, the treatment of stroke, and therapy for viral infections that included HIV, HCV and RSV. Most notably, his work has resulted in the approval of several drugs including fostemsavir, a phosphonooxymethyl prodrug of temsavir, approved by the FDA on July 2, 2020, and marketed as Rukobia™ for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection; daclatasvir (Daklinza™), a pioneering molecule that established HCV NS5A inhibition as a clinically-relevant target; asunaprevir (Sunvepra™), an HCV NS3 protease inhibitor incorporating the cyclopropyl acylsulfonamide moiety that has been widely adopted; and beclabuvir, a thumb site inhibitor of HCV NS5B polymerase. Both daclatasvir and asunaprevir were marketed as a combination therapy for the treatment of HCV genotype 1b infection. In addition, beclabuvir was approved in Japan in December 2016 for the treatment of HCV genotype 1 infection as part of a fixed dose combination with daclatasvir and asunaprevir, marketed as Xymency™. He has coauthored over 260 peer-reviewed articles and 25 book chapters, edited 2 books, and is an inventor of over 140 issued US patents. He has given over 200 presentations, seminars, lectures, short courses, and workshops. He has served in the editorial boards of a number of journals. Nick received many awards for his pioneering drug discovery work including being a co-recipient of a *PhRMA Research and Hope Award for Biopharmaceutical Industry Research* in 2014 for outstanding research in the area of HIV/AIDS; recipient of the *2015 Philip S. Portoghese Medicinal Chemistry Lectureship Award* administered jointly by the *ACS Division of Medicinal Chemistry* and the *Journal of Medicinal Chemistry*, induction into the ACS Division of Medicinal Chemistry Hall of Fame in 2015; a co-recipient of a 2017 ACS “Heroes of Chemistry” Award; recipient of the *2022 ACS Alfred Burger Award in Medicinal Chemistry*, and a 2022 ACS Fellow.